5 completed, 1 recruiting, 1 unknown. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Recruiting 1, Unknown 1 |
| Phase 2 | 1 | Completed 1 |
Follow Dermatitis, Seborrheic: new trials by email Literature Review of Dermatitis, Seborrheic trials Research Report on Dermatitis, Seborrheic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Roflumilast Foam 0.3% in Trial Participants With Seborrheic Dermatitis Roflumilast Foam 0.3%, Vehicle foam - Seborrheic Dermatitis | Phase 3 | Recruiting | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | 309 | 2026-11-12 | 2026-11-17 |
| Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) Roflumilast Foam, Vehicle Foam - Seborrheic Dermatitis | Phase 3 | Completed | Arcutis Biotherapeutics, Inc. | 457 | 2021-07-08 | 2024-03-12 |
| Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis Protopic (R), Mycoster (R) - Severe Seborrheic Dermatitis | Phase 3 | Completed | University Hospital, Rouen | 120 | 2014-01-01 | 2018-05-29 |
| Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis 0.5% prednisolone acetate cream, 0.1% betamethasone valerate cream - Dermatitis, Atopic, Dermatitis, Contact | Phase 3 | Unknown | Mantecorp Industria Quimica e Farmaceutica Ltd. | 170 | 2010-02-01 | 2009-11-11 |
| K301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp K301, Placebo - Seborrhoeic Eczema of the Scalp | Phase 3 | Completed | Moberg Pharma AB | 201 | 2008-02-01 | 2010-06-04 |
| Efficacy and Safety of ASF1057 in the Treatment of Seborrhoeic Dermatitis ASF1057 - Seborrheic Dermatitis | Phase 3 | Completed | Astion Pharma A/S | 300 | 2007-12-01 | 2008-06-03 |
| Two Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp K40a, K40b, Placebo - Seborrhoeic Dermatitis of the Scalp | Phase 2 / Phase 3 | Completed | Moberg Pharma AB | 98 | 2007-02-01 | 2010-06-04 |
Dandruff (1) · Dermatitis, Atopic (1) · Dermatitis, Contact (1) · Psoriasis (1)
Dermatitis (7) · Sebaceous Gland Diseases (7) · Skin Diseases (7) · Skin Diseases, Eczematous (7) · Skin Diseases, Papulosquamous (7) · Skin and Connective Tissue Diseases (7) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hypersensitivity (1) · Hypersensitivity, Immediate (1) · Immune System Diseases (1) · Scalp Dermatoses (1) · Skin Diseases, Genetic (1)
Ciclopirox (1) · Tacrolimus (1)
Moberg Pharma AB (2) · Arcutis Biotherapeutics, Inc. (1) · Astion Pharma A/S (1) · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (1) · Mantecorp Industria Quimica e Farmaceutica Ltd. (1) · University Hospital, Rouen (1)
Sweden (2) · Canada (1) · China (1) · France (1) · United States (1)
Adilson Costa, MD (1) · David Berk, MD (1) · Lennart Emtestam, MD (1) · Peder M Andersen, MD (1) · Roberta F. J. Criado, MD (1)